January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

Eli Lilly and venture capital firm Andreessen Horowitz ... s R&D expertise to “foster a technology ecosystem of ambitious bio + health entrepreneurs and innovators,” according to a Jan ...

In an apparently unprecedented move, Eli Lilly is partnering with the fabled ... Vineeta Agarwala, a partner at Andreessen’s biotech arm, a16z Bio + Health, said the deal aims to combine ...

Andreessen Horowitz noted on the 10th (local time) that it will collaborate with Eli Lilly to create the first venture capital fund aimed at promoting extensive innovation in the bio sector.

Bio + Health today announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health, in partnership with Eli Lilly and Company (“Lilly”). The Biotech ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Verdiva Bio has raised more than $410mn in one of the biggest initial funding rounds in the biotech sector ...